Literature DB >> 8557689

Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases.

K Loughney1, T J Martins, E A Harris, K Sadhu, J B Hicks, W K Sonnenburg, J A Beavo, K Ferguson.   

Abstract

cDNAs corresponding to two human calcium, calmodulin (CaM)-regulated 3',5'-cyclic nucleotide phosphodiesterases (PDEs) were isolated. One, Hcam1 (PDE1A3), corresponds to the bovine 61-kDa CaM PDE (PDE1A2). The second, Hcam3 (PDE1C), represents a novel phosphodiesterase gene. Hcam1 encodes a 535-amino acid protein that differs most notably from the bovine 61-kDa CaM PDE by the presence of a 14-amino acid insertion and a divergent carboxyl terminus. RNase protection studies indicated that Hcam1 is represented in human RNA from several tissues, including brain, kidney, testes, and heart. Two carboxyl-terminal splice variants for Hcam3 were isolated. One, Hcam3b (PDE1C1), encodes a protein 634 amino acids (72 kDa) in length. The other, Hcam3a (PDE1C3), diverges from Hcam3b 4 amino acids from the carboxyl terminus of Hcam3b, and extends an additional 79 amino acids. All the cDNAs isolated for Hcam3a are incomplete; they do not include the 5'-end of the open reading frame. Northern analysis revealed that both splice variants were expressed in several tissues, including brain and heart, and that there may be additional splice variants. Amino-truncated recombinant proteins were expressed in yeast and characterized biochemically. Hcam3a has a high affinity for both cAMP and cGMP and thus has distinctly different kinetic parameters from Hcam1, which has a higher affinity for cGMP than for cAMP. Both PDE1C enzymes were inhibited by isobutylmethylxanthine, 8-methoxymethyl isobutylmethylxanthine, zaprinast, and vinpocetine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557689     DOI: 10.1074/jbc.271.2.796

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Authors:  Isaac Levy; Anelia Horvath; Monalisa Azevedo; Rodrigo Bertollo de Alexandre; Constantine A Stratakis
Journal:  Curr Opin Pharmacol       Date:  2011-10-31       Impact factor: 5.547

Review 2.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

3.  Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase.

Authors:  S Spence; G Rena; M Sullivan; S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

4.  PDE1A inhibition elicits cGMP-dependent relaxation of rat mesenteric arteries.

Authors:  Makhala Michell Khammy; Thomas Dalsgaard; Peter Hjørringgaard Larsen; Claus Tornby Christoffersen; Dorte Clausen; Lars Kyhn Rasmussen; Lasse Folkersen; Morten Grunnet; Jan Kehler; Christian Aalkjaer; Jacob Nielsen
Journal:  Br J Pharmacol       Date:  2017-10-15       Impact factor: 8.739

5.  Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.

Authors:  G B Bolger; S Erdogan; R E Jones; K Loughney; G Scotland; R Hoffmann; I Wilkinson; C Farrell; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

Review 6.  An update on vinpocetine: New discoveries and clinical implications.

Authors:  Yi-Shuai Zhang; Jian-Dong Li; Chen Yan
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

7.  A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression.

Authors:  P Calabresi; P Gubellini; D Centonze; G Sancesario; M Morello; M Giorgi; A Pisani; G Bernardi
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

Review 8.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

9.  Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells.

Authors:  X Jiang; J Li; M Paskind; P M Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.

Authors:  S D Rybalkin; K E Bornfeldt; W K Sonnenburg; I G Rybalkina; K S Kwak; K Hanson; E G Krebs; J A Beavo
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.